^
Association details:
| Biomarker: | ARAF mutation + NRAS mutation |
|---|---|
| Cancer: | Melanoma |
| Drug: | belvarafenib (RG6185) (pan-RAF inhibitor) |
| Direction: | Resistant |
Evidence:
Source:
Title:
ARAF mutations confer resistance to the RAF inhibitor belvarafenib in melanoma.
Published date:
05/05/2021
Excerpt:
...belvarafenib-resistant NRAS-mutant melanoma cells and analysing circulating tumour DNA from patients treated with belvarafenib, we identified new recurrent mutations in ARAF within the kinase domain. ARAF mutants conferred resistance to belvarafenib in both a dimer- and a kinase activity-dependent manner.
DOI:
https://doi.org/10.1038/s41586-021-03515-1
